Wednesday, February 15, 2023
Clinician Perspectives on the Potential of DBS for Pediatric Patients with Treatment-Resistant OCD
(Conferences / Seminars / Lectures)
Update: This seminar is postponed and will not take place on February 15. It will be rescheduled for a future date to be determined. more information...
Join us for this free webinar from Michelle T. Pham, PhD, presented as part of the 2022-2023 Bioethics Public Seminar Series. Register: https://bit.ly/bioethics-pham
The World Society for Stereotactic and Functional Neurosurgery has argued that at least two successful randomized controlled trials should be available before deep brain stimulation (DBS) treatment for a psychiatric disorder is considered "established." DBS is currently offered to children ages 7 and older with refractory dystonia under an FDA-humanitarian device exemption. No randomized control trials were conducted - practitioners relied on evidence from DBS use in adults. In addition, accumulated research supports the safety and effectiveness of DBS for obsessive-compulsive disorder (OCD) in adults (Wu et al. 2021). Approximately 10-20% of children with OCD have treatment-resistant presentations, so it is likely that there will be interest in offering DBS for some children (POTS 2004). Both ethical and empirical anticipatory work is needed to evaluate whether, and if so, under what conditions it might be appropriate to offer DBS in this context. This seminar will present qualitative data from semi-structured interviews with 24 clinicians with expertise in this area regarding: (a) acceptable levels of evidence to offer DBS in this patient population and (b) institutional policies or protocols needed to effectively provide care for them.